Burkitt morphology
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia are not eligible
Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.
Mature B-cell (Burkitt's) ALL
. High Grade B-cell Lymphoma---Burkitt's like.
Burkitt's lymphoma: second or subsequent CR
Burkitt lymphoma
Burkitt lymphoma/leukemia
Patients with Burkitt lymphoma/leukemia
Burkitt lymphoma
Burkitt cell or mixed lineage acute leukaemia
Patients with CLL, Burkitt or lymphoblastic lymphoma are excluded
Burkitt's lymphoma: second or subsequent CR
Patients with Burkitt lymphoma/leukemia
Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [surface Immunoglobulin (sIg) positive and kappa or lambda restricted positivity] ALL, with FAB L morphology and /or a MYC translocation)
Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L morphology and /or a MYC translocation)
Patients must have Burkitt lymphoma; effective with Amendment J (version date: //), the following histologies were removed: B-cell lymphoma: unclassifiable with features intermediate between diffuse large Bcell lymphoma and Burkitt lymphoma; c-MYC + DLBCL and c-MYC+ plasmablastic lymphoma\r\n* If questions arise related to diagnosis, please contact the National Cancer Institute (NCI) principle investigator, Dr. Mark Roschewski or the NCI study coordinator, A. Nicole Lucas
EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma
Histologically or cytologically proven B-cell malignancies; either Burkitt leukemia or B-AL (= Burkitt leukemia = L-AL), or diffuse large B-cell NHL, or aggressive mature B-cell NHL non otherwise specified or specifiable (phase III)\r\n* Stage III with elevated LDH level (B-high) (LDH > twice the institutional upper limit of the adult normal values [> Nx]), any stage IV, or B-AL (phase III)
Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma or mantle cell lymphoma (MCL).
Histologically or cytologically proven B-cell malignancies, either Burkitt lymphoma or B-AL (=Burkitt leukaemia = L-AL) or diffuse large B-cell NHL or aggressive mature B-cell NHL non other specified or specifiable.
CLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant or has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
Burkitt and/or precursor lymphoblastic leukemia/lymphoma
Burkitt, mantle cell, follicular, or mucosa-associated lymphoid tissue lymphoma
Patients with Burkitt's leukemia/lymphoma.
